Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma
Status:
Withdrawn
Trial end date:
2025-02-20
Target enrollment:
Participant gender:
Summary
The primary objective is to estimate the efficacy of experimental treatment with the
anti-PD-1 antibody cemiplimab (REGN2810) in combination with simultaneous or subsequent
radiotherapy (RT) in early-stage favorable classical Hodgkin lymphoma (cHL).
Secondary objectives are to assess the safety and feasibility of the 2 experimental
strategies.